--- title: "Apellis Pharma (APLS.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/APLS.US.md" symbol: "APLS.US" name: "Apellis Pharma" industry: "Biotechnology" datetime: "2026-05-20T23:45:37.563Z" locales: - [en](https://longbridge.com/en/quote/APLS.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/APLS.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/APLS.US.md) --- # Apellis Pharma (APLS.US) ## Company Overview Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:15.000Z **Overall: B (0.28)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 0 / 386 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 42.46% | | | Net Profit YoY | 159.58% | | | P/B Ratio | 0.00 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 0.00 | | | Revenue | 1105280000.00 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 46.02% | A | | Profit Margin | 12.06% | B | | Gross Margin | 56.20% | B | | Revenue YoY | 42.46% | A | | Net Profit YoY | 159.58% | A | | Total Assets YoY | 34.10% | A | | Net Assets YoY | 152.67% | A | | Cash Flow Margin | 28.34% | D | | OCF YoY | 42.46% | A | | Turnover | 1.17 | A | | Gearing Ratio | 61.67% | D | ```chart-data:radar { "title": "Longbridge Financial Score - Apellis Pharma", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "42.46%", "rating": "" }, { "name": "Net Profit YoY", "value": "159.58%", "rating": "" }, { "name": "P/B Ratio", "value": "0.00", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "0.00", "rating": "" }, { "name": "Revenue", "value": "1105280000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "46.02%", "rating": "A" }, { "name": "Profit Margin", "value": "12.06%", "rating": "B" }, { "name": "Gross Margin", "value": "56.20%", "rating": "B" }, { "name": "Revenue YoY", "value": "42.46%", "rating": "A" }, { "name": "Net Profit YoY", "value": "159.58%", "rating": "A" }, { "name": "Total Assets YoY", "value": "34.10%", "rating": "A" }, { "name": "Net Assets YoY", "value": "152.67%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "28.34%", "rating": "D" }, { "name": "OCF YoY", "value": "42.46%", "rating": "A" }, { "name": "Turnover", "value": "1.17", "rating": "A" }, { "name": "Gearing Ratio", "value": "61.67%", "rating": "D" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 39.41 | 51/386 | 122.30 | 69.33 | 58.11 | | PB | 12.66 | 404/386 | 18.74 | 13.59 | 6.88 | | PS (TTM) | 4.75 | 99/386 | 4.62 | 3.12 | 2.69 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-04-29T04:00:00.000Z Total Analysts: **20** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 5% | | Hold | 19 | 95% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 41.06 | | Highest Target | 41.00 | | Lowest Target | 40.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/APLS.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/APLS.US/norm.md) - [Related News](https://longbridge.com/en/quote/APLS.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/APLS.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**